Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model.
OBJECTIVE
We analyzed the effect of intraperitoneal immunotherapy in an animal model mimicking locoregional dissemination of tumor cells during resection of advanced tumors.


METHODS
We first established a tumor model with human gastric cancer cells (MKN-45) in the peritoneal cavity of CB-17-SCID mice. Three hours following the injection of tumor cells into the peritoneal cavity, mAb 17-1A alone and in combination with human LAK cells were given intraperitoneally at different dosages. The results were quantified by determining the weight of the peritoneal tumor masses.


RESULTS
After intraperitoneal administration of 17-1A mAb, a tumor reduction could be shown (median tumor mass after 10 microg mAb: 171 microg; after 100 microg: 130 microg) when compared with the control group (632 microg). Following a combined therapy with mAb and LAK cells, a statistically significant tumor reduction could be observed (after 10 microg mAb + 20-50 x 10(6) LAK cells: 80 microg; after 100 microg mAb + 20-50 x 10(6) LAK cells: 12 microg, p = 0.0005). With specific dosages of antibody and LAK cells it was even possible to achieve complete tumor clearance.


CONCLUSIONS
Intraperitoneal immunotherapy reduces the peritoneal tumor masses and can even prevent the peritoneal carcinomatosis formation.
Klinik für Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Germany. piso.pompiliu@mh-hannover.de
P
P
Piso
H
H
Aselmann
R
R
von Wasielewski
M H
MH
Dahlke
J
J
Klempnauer
H J
HJ
Schlitt
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007274:Injections, Intraperitoneal; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D013274:Stomach Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D023041:Xenograft Model Antitumor Assays
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; C400149:Edrecolomab